<DOC>
	<DOCNO>NCT00788372</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy fentanyl one-day transdermal patch ( JNS020QD , patch contain drug put skin drug enter body skin ) participant chronic ( last long time ) pain .</brief_summary>
	<brief_title>An Efficacy Safety Study Fentanyl Participants With Chronic Pain</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , multi-center ( conducted one center ) non-comparative study fentanyl one-day transdermal patch . The study consist 4 period : Screening period ( 3-14 day ) , Treatment period 1 ( 4 week ) , Treatment period 2 ( 48 week ) , Tapering period ( 0-6 week ) Follow-up period ( 1 week ) . Treatment initiate 12.5 microgram per hour ( mcg/hr ) . In Treatment period 1 2 , dose increase per Investigator 's discretion , range 12.5 mcg/hr 100 mcg/hr maximum application dose 300 mcg/hr . However , Treatment period 2 , dose increase 7th day day medical examination ( participant use rescue treatment minimum 3 time per day minimum 4 day ) . The patch apply area include chest , abdomen , upper arm femoral region replace daily . Efficacy primarily evaluate visual analog scale ( VAS ) score . The total duration study treatment 52 week . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Fentanyl</mesh_term>
	<criteria>Participants whose medication chronic pain meet one criterion among e ( 2 type opioid analgesic must use ) : ) Participants take nonopioid analgesic normal high dose least 14 consecutive day 12 week informed consent , continuously take nonopioid analgesic 14 day inform consent medical reason safety b ) Participants continuously take additional analgesic certain dosage administration least 14 consecutive day inform consent c ) Participants continuously take codeine phosphate dihydrocodeine phosphate le 270 milligram ( mg ) daily ( except rescue treatment ) least 14 consecutive day inform consent ) Participants continuously take codeine morphine hydrochloride oral morphine equivalent dose le 45 mg daily ( except rescue treatment ) least 14 consecutive day inform consent ( le 30 mg daily suppository less 15 mg daily injection ) e ) Participants continuously take fentanyl citrate injection le 0.3 mg daily ( except rescue treatment ) least 14 consecutive day inform consent Participants chronic pain continue least 12 week inform consent Participants average pain intensity great equal 50 millimeter ( mm ) Visual Analog Scale 24hour daily living inform consent Participants hospitalize 4th day initiation patch application Participants give sufficient explanation investigational product study give consent participate study Participants whose main cause pain assess consider attributable psychogenic pain Participants severe respiratory function disorder Participants asthma ( breathe disorder wheeze difficulty breathe ) bradyarrhythmia ( slow , irregular heartbeat ) Participants hepatic dysfunction function fulminant hepatitis ( inflammation liver ) liver cirrhosis ( serious liver disorder connective tissue replaces normal liver tissue , liver failure often occur ) , renal impairment nephritic syndrome , acute renal failure , chronic renal failure Participants organic disorder brain brain tumor symptom : intracranial pressure increase , consciousness disturbance coma respiratory disorder</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Chronic pain</keyword>
	<keyword>Fentanyl Patch</keyword>
</DOC>